Cefuroxime axetil
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Zinnat, Ceftin, Ceftum |
Other names | Cefuroxime 1-acetoxyethyl ester |
Routes of administration | Oral, IV, IM |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | well absorbed |
Metabolism | Cefuroxime is not metabolized, Axetil is metabolized to acetaldehyde and acetic acid. |
Excretion | Urine |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.166.374 |
Chemical and physical data | |
Formula | C20H22N4O10S |
Molar mass | 510.475 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 as Zinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US[3] and Ceftum in India.[4]
It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.[5] The activity depends on in vivo hydrolysis and release of cefuroxime tablets.
See also
- Cefuroxime
- ( )
References
- ^ "Our history - About GSK". GlaxoSmithKline. Archived from the original on 2011-05-14.
{{cite web}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ "Cefuroxime Axetil Monograph for Professionals". Drugs.com. Retrieved 2018-04-22.
- ^ "Brands". Gsksource.com. 2018-03-22. Retrieved 2018-04-22.
- ^ "Our products". GlaxoSmithKline.
- ^ Walter Sneader (2005-06-23). Drug Discovery: A History. John Wiley, Chichester, UK. ISBN 0-471-89979-8.